PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1320222
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1320222
Recombinant Erythropoietin Market size was valued at USD 6,851.28 Million in 2022, expanding at a CAGR of 2.1% from 2023 to 2030.
Recombinant erythropoietin (rEPO) is a genetically modified type of erythropoietin, a hormone generated normally in the kidneys that controls red blood cell synthesis. rEPO is created through biotechnology, often using mammalian cells. It possesses the same form and function as endogenous erythropoietin and is utilized for treating anemia-related illnesses including chronic kidney failure, cancer-related anemia, and anemia caused by certain medicinal therapies. rEPO increases oxygen-carrying capacity in the blood by promoting the synthesis of red blood cells, enhancing energy levels, and minimizing the requirement for blood transfusions in patients with anemia.
The rising frequency of chronic kidney disease (CKD) and the necessity for efficient anemia therapy is driving demand for recombinant erythropoietin (rEPO). Anaemia is common in CKD patients due to decreased erythropoietin production. rEPO, also known as Epoetin Alfa, is used to increase red blood cell formation, easing anemia symptoms and minimizing the requirement for blood transfusions. As the worldwide prevalence of CKD climbs owing to reasons such as aging populations and lifestyle changes, the healthcare sector's need for rEPO as a vital therapeutic option for anemia treatment in CKD patients grows.
The Global Recombinant Erythropoietin Market is segmented on the basis of Type, Indication, End-Use, and Region.
The market is divided into two categories based on Type: Epoetin Alfa, Darbepoetin Alfa. Epoetin Alfa, a kind of recombinant erythropoietin (rEPO), is in high demand since it is frequently used to treat anemia caused by chronic kidney disease, cancer chemotherapy, and other medical diseases. Epoetin Alfa promotes red blood cell synthesis, which helps to reduce anemia symptoms and enhance patients' quality of life.
The market is divided into four categories based on Indication: Anemia Associated with Chronic Kidney Disease (CKD), Cancer Related Anemia, HIV-Associated Anemia, Others. The Cancer Related Anemia sector dominates the market and is likely to maintain its dominance during the forecast period. In the treatment of cancer-related anemia, recombinant erythropoietin (rEPO) is in great demand. Patients taking chemotherapy for cancer often have a reduction in red blood cell formation, resulting in anemia. rEPO, especially Epoetin Alfa, is used to increase red blood cell synthesis, lowering the need for blood transfusions and increasing the general well-being of cancer patients.
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Several reasons contribute to the high demand for recombinant erythropoietin (rEPO) in the Asia Pacific area. A considerable patient population in the area suffers from anemia-related illnesses such as chronic renal disease and cancer. Furthermore, the region's rapidly aging population and rising frequency of chronic illnesses boost demand for rEPO as a treatment option for anemia management. Furthermore, improving healthcare infrastructure as well as medical technology improvements led to the increased usage of rEPO in the Asia Pacific market. As a consequence, pharmaceutical firms are increasing their presence in the area to address the increasing demand for rEPO and other biologics.
Because of its critical function in treating anemia-related disorders, recombinant erythropoietin (rEPO) faces severe competition. Several pharmaceutical firms are involved in the development and marketing of rEPO, creating a competitive environment. The market is dominated by key firms with well-established brands and substantial distribution networks. Companies strive for a competitive advantage by emphasizing product efficacy, safety, and cost-effectiveness. Furthermore, continuous R&D activities seek to enhance formulations and administration modalities, boosting patient comfort and compliance. The competitive dynamics are further influenced by strict regulatory compliance and patent protection.
In February 2023, The Food and Drug Administration authorised Jesduvroq tablets (daprodustat) as the first oral medication for anaemia (low red blood cell count) caused by chronic renal disease in individuals who have been receiving on dialysis for at least a four-month period. Jesduvroq is not authorised for non-dialysis patients. Other FDA-approved therapies for this illness are administered through injection into the bloodstream or via the skin.
The scope of this report covers the market by its major segments, which include as follows: